Sequenom IPO Prospectus Shows Diagnostics Potential In Product Pipeline
This article was originally published in The Gray Sheet
Executive Summary
Potential applicability of Sequenom, Inc.' s industrial genomics technology to the field of diagnostics is outlined in a preliminary prospectus for an initial public offering of up to $70 mil. in common stock, recently filed with the Securities and Exchange Commission.
You may also be interested in...
Sequenom
Development stage industrial genomics firm grosses $157 mil. in initial public offering of approximately 6 mil. shares at $26 per share on Feb. 1, including 787,500 overallotment shares. San Diego-based Sequenom outlined plans for the offering late last year (1"The Gray Sheet" Dec. 13, p. 19). The proceeds will be used for expansion of sales, customer support and facilities, as well as continued product development, R&D, debt repayment and other general corporate purposes. The stock trades on the Nasdaq exchange under the symbol "SQNM." Underwriters included Warburg Dillon Read, Robertson Stephens and SG Cowen
Sequenom
Development stage industrial genomics firm grosses $157 mil. in initial public offering of approximately 6 mil. shares at $26 per share on Feb. 1, including 787,500 overallotment shares. San Diego-based Sequenom outlined plans for the offering late last year (1"The Gray Sheet" Dec. 13, p. 19). The proceeds will be used for expansion of sales, customer support and facilities, as well as continued product development, R&D, debt repayment and other general corporate purposes. The stock trades on the Nasdaq exchange under the symbol "SQNM." Underwriters included Warburg Dillon Read, Robertson Stephens and SG Cowen
Caliper's $46 Mil. IPO To Fund LabChip Manufacturing Scale-Up, R&D
Development of "lab-on-a-chip" technologies used in high-throughput nucleic acid analysis for diagnostics applications is one of several development projects that would benefit from Caliper Technologies' $46 mil. initial public offering.